why don't you spell it out Ralom - or is your comment just wishful thinking?
now I fully realise that stock prices move ahead of profitability (I've only been a market observer for nearly 30 years) so normally, I might agree with you - there is usually scope for sp improvement prior to profitability. But AHZ has another problem doesn't it?
the problem, as I see it, is AHZ's massive share register. Some no doubt think that an sp of 50c/$1 is somewhere close at hand (or at least in the near future) but stop and think how many patches you need to flog to cover a company with 1.6 billion shares fully diluted at those prices.
maybe the vaccine program can pull the chook out of the fire? - but Phase II trial results have to be 2/3 years away? and at this stage there is no certainty of success - (read AHZ's FY report before posting something stupid about Phase II results).
so for me, AHZ has a long hard grind in front of it. It's screwed on several fronts IMO in terms of any quick outcomes for sp rises. AHZ might have a great product and some expectation of a success at Ph II trials but it's gonna be hard watching it move slower than a tortoise....
I'm not telling anyone what to do here, just explaining my POV. I know what I'm gonna do.
- Forums
- ASX - By Stock
- News: Admedus revenue up 7.09% for FY2014
why don't you spell it out Ralom - or is your comment just...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.91 |
Change
-0.090(0.50%) |
Mkt cap ! $344.2M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.75 | $74.32K | 4.151K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 681 | $17.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.25 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 681 | 17.900 |
1 | 1 | 17.800 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
Price($) | Vol. | No. |
---|---|---|
18.250 | 100 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online